enGene Announces Partnership with Janssen Biotech to Develop New Therapies for Inflammatory Bowel Diseases

enGene Announces Partnership with Janssen Biotech to Develop New Therapies for Inflammatory Bowel Diseases
enGene, Inc., a privately held biotechnology company developing a versatile non-viral vector platform for gene delivery through its proprietary technology “Gene Pill”, recently announced that it has made a decisive agreement with Janssen Biotech, Inc. for the development and commercialization of new treatments for patients with inflammatory bowel diseases (IBD). Under the terms of the agreement, enGene will receive an upfront payment, equity investment through Johnson & Johnson Innovation – JJDC, Inc., and R&D funding. The company is also qualified to receive diverse pre-clinical, clinical, regulatory and commercialization accomplishment-based payments up to an amount of C $441 million, as well as tiered royalties on prospective net sales of its clinical products. The collaboration empowers the company’s proprietary non-viral vector platform for gene delivery to cells lining the intestine. The vector system can be administered to the intestine orally or via enema route. This cooperation offers Janssen the possibility to wholly license EG-12, enGene’s lead product that consists of a unique carrier-DNA complex that provides gut-localized expression of interleukin (IL)-10, being developed for the treatment of ulcerative colitis. IL-10 is an anti-inflammatory cytokine, and individuals with genetic defects within the IL-10 signaling pathway can suffer from severe early-onset inflammation of the gut. EG-12 will be jointly developed by the companies to provide clinical proof of mechanism in IBD patients. The partnership also consents Janssen to investigate the therapeutic potential of enGene’s platform to produce one supplementary unrevealed target. “
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *